arkinson disease is a major neurodegenerative disorder characterized by a progressive loss of dopamine neurons in the substantia nigra, resulting in a severe deficiency of dopamine in the striatum. Dopamine-replacement strategies involving levodopa are initially effective, but reduced efficacy and development of unbearable motor complications require alternative treatments. Transplantation of grafts supplying dopamine in the striatum is a rational consideration as a treatment for patients with PD. Many kinds of tissues and cells have been tested as sources of dopamine, but transplantation therapy is now recognized to be effective only if grafts work like the original dopamine neurons, modulating functions under physiological conditions.
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arkinson disease is a major neurodegenerative disorder characterized by a progressive loss of dopamine neurons in the substantia nigra, resulting in a severe deficiency of dopamine in the striatum. Dopamine-replacement strategies involving levodopa are initially effective, but reduced efficacy and development of unbearable motor complications require alternative treatments. Transplantation of grafts supplying dopamine in the striatum is a rational consideration as a treatment for patients with PD. Many kinds of tissues and cells have been tested as sources of dopamine, but transplantation therapy is now recognized to be effective only if grafts work like the original dopamine neurons, modulating functions under physiological conditions. 18 To obtain sufficient functional dopamine neurons for transplantation, stem cells, having the capapacity for both self-renewal and differentiation into a variety of phenotypes, have been actively investigated. There are several types of stem cells that have been proven to differentiate into dopamine neurons, and optimal methods of differentiation and effectiveness of transplantation have been reported. 33 Recently, SKP cells have attracted attention because they are readily accessible pluripotent sources that can be reliably induced to undergo neuronal differentiation. 5, 36 However, there has been no study on whether SKPs can effectively differentiate into dopamine neurons and actually produce dopamine in the brain, contributing to functional recovery from PD-like symptoms.
The VHL protein has been shown to cause undifferSkin-derived precursors differentiating into dopaminergic neuronal cells in the brains of Parkinson disease model rats
Laboratory investigation entiated cells to demonstrate neuronal phenotypes.
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We have intensively examined VHL protein as one of the most effective tools for inducing neuronal differentiation. Elongin C is a major protein that induces ubiquitin-dependent neuronal differentiation of progenitor cells. The VHL protein directly binds to and activates Elongin C. The site in the VHL protein to which Elongin C binds is amino acids 157-171. We showed in previous studies that even this small fragment of VHL protein, amino acids 157-171 (VHL peptide), can effectively induce neuronal differentiation of not only neuronal progenitor cells but also SKPs. Moreover, transplantation of these differentiated SKPs into the striata of a PD model in rats resulted in a remarkable decrease in the number of apomorphineinduced rotations. 12, 17 These findings provide evidence for a new transplantation therapy for PD using SKPs differentiated with VHL peptide; however, the reason the number of rotations is reduced has not been clarified. Therefore, the purpose of this study was to confirm that transplanted cells survive in the brain and work as dopaminergic neuronal cells, effectively producing dopamine to improve PD-like symptoms. Here, we provide evidence supporting the therapeutic potential of SKPs in PD.
Methods

The VHL Peptide and SKP Preparation
A peptide matching amino acids 157-171 of VHL protein (VHL peptide; TLKERCLQVVRSLVK) was chemically synthesized using the 9-fluorenylmethyloxycarbonyl solid phase method. The VHL peptide was linked at the N-terminus to protein transduction domains derived from the HIV Tat protein (TAT; YGRKKRRQR-RRD).
The SKPs were cultured as previously described.
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Briefly, dorsal back skin from rat neonates (postneonatal Days 1-3) was cut into 2-3-mm 2 pieces. Tissue was digested with 0.1% trypsin for 40 minutes at 37°C, followed by 0.1% DNase (Sigma) for 1 minute at room temperature. It was then mechanically dissociated and filtered through a 40-µm cell strainer (Falcon, BD Bioscience). Dissociated cells were centrifuged and resuspended in DMEM/F-12 (3:1; Gibco-Invitrogen) containing 2% B27 supplement, 20 ng/ml epidermal growth factor (Upstate Biotechnology), and 40 ng/ml basic fibroblast growth factor (PeproTech). Cells were cultured at 37°C in a 5% CO 2 tissue-culture incubator. To passage SKPs, floating spheres were mechanically dissociated and reseeded in fresh medium containing B27 and growth factors, as described above, at a density of 1 × 10 5 cells/ml. Cells were passaged every 7 days.
To induce differentiation, SKP spheres were dissociated with trypsin, and 1 µM VHL peptide linked with TAT (VHL-TAT) was added to the medium. After incubation at 37°C for 24 hours, cells were counted and collected for transplantation.
Immunocytochemistry
Immunocytochemical analysis was performed to determine the localization of VHL peptide in SKPs and to evaluate the differentiation of SKPs. After incubating SKPs on chamber slides with VHL-TAT or FITC-labeled VHL-TAT as appropriate, cells were fixed with 4% paraformaldehyde and this was followed by blocking with 2% bovine serum albumin in 10% normal donkey serum. Cells were incubated with primary antibodies overnight at 4°C. Primary antibodies and dilutions were as follows: 1:250 mouse anti-MAP-2 (Sigma); 1:250 rabbit anti-TH (Chemicon); 1:250 rat anti-DAT (Chemicon); and 1:400 mouse antiglial fibrillary acidic protein (Chemicon). In negative control studies, phosphate-buffered saline was substituted for the antibodies. Cells were then incubated with secondary antibody for 3 hours at room temperature. We used 1:200 FITC-conjugated anti-mouse IgG, 1:200 200 tetramethylrhodamine isothiocyanate-conjugated anti-rabbit IgG, and 1:200 200 tetramethylrhodamine isothiocyanate-conjugated anti-rat IgG (Chemicon) as the secondary antibodies as appropriate. For counterstaining, DAPI (Molecular Probes) was used. Fluorescence signal was observed using a laser scanning confocal microscope (FluoView FV300, Olympus) with a sequential scanning model.
Immunoprecipitation and Western Blot Analysis
Binding of the VHL peptide to Elongin C in SKPs was determined by immunoprecipitation and Western blot analysis. The SKP spheres were dissociated with trypsin, and 1 µM FITC-labeled VHL-TAT was added to the medium. After incubation at 37°C for 24 hours, SKPs were lysed in lysis buffer (M-PER, Pierce Biotechnology) and clarified by centrifugation. This sample was incubated with goat anti-Elongin C (Santa Cruz Biotechnology) at 4°C for 1 hour. Immune complexes were precipitated with protein G Sepharose (Amersham Biosciences). After washing 3 times with lysis buffer, immunoprecipitates were separated by 12.5% sodium dodecyl sulfateñpolyacrylamide gel electrophoresis under reducing conditions and transferred onto polyvinylidene fluoride membranes (Immobilon-P, Millipore) for Western blot analysis. After blocking with 5% nonfat milk in 20 mM Tris-buffered saline containing 0.1% Tween 20 for 1 hour at room temperature, rabbit anti-FITC antibody (Zymed Labs) was applied as a primary antibody. As a loading control, we used 1:10,000 mouse monoclonal anti-human β-actin (Sigma); as secondary antibodies, 1:10,000 horseradish peroxidase-linked anti-mouse IgG and 1:10,000 horseradish peroxidase-linked anti-rabbit IgG (Amersham Biosciences) were used. Immunoreactive proteins were visualized using an ECL Plus Detection Kit (Amersham Biosciences).
Parkinson Disease Rat Model
The PD rat model was made using 6-OHDA as described previously. 38 Briefly, adult male Wistar rats, weighing 250-300 g, pretreated with desipramine (25 mg/kg intraperitoneally) were anesthetized with sodium pentobarbital (40 mg/kg intraperitoneally). Stereotactic injection of 6-OHDA (8 µg in 4 µl of 0.1% ascorbate-saline; Sigma) into the left medial forebrain bundle (4.4 mm posterior to the bregma, 1.1 mm lateral to the bregma, and 7.7 mm ventral from the dural surface). Two weeks after 6-OHDA injection, rats showing average contralateral ro-tations of more than 6 per minute with apomorphine injection (0.1 mg/kg subcutaneously; Sigma) were selected for transplantation. All animal experimental procedures were approved by the Institutional Animal Use Committee of Yokohama City University and performed were in accordance with NIH guidelines for care and use of laboratory animals.
The SKPs (1 × 10 6 ) treated with VHL-TAT and labeled with Hoechst 33342 (Dojindo) were stereotactically transplanted using a 10-μl Hamilton syringe at an injection rate of 1.0 μl/minute into the left striatum (0.5 mm anterior, 3.0 mm lateral to the bregma, and 4.5 mm ventral from the dural surface) of each of lesioned rats (VHL-SKP group; 7 animals). As controls, 1 × 10
6 SKPs not treated with VHL-TAT but labeled with Hoechst were transplanted into each of the other lesioned rats in the same procedure (SKP group; 7 animals). Four weeks after transplantation, apomorphine-induced rotation was counted to evaluate the improvement of rotational behavior.
Microdialysis
Six weeks after transplantation of SKPs, under sodium pentobarbital anesthesia (31.5 mg/kg intraperitoneally), a stainless-steel guide cannula (outer diameter 0.51 mm; AG-4, Eicom Co.) was implanted stereotactically into the denervated and grafted striatum. The coordinates were 0.5 mm anterior from the bregma, 3.0 mm lateral to the midline, and 4.0 mm below the surface of the brain. The anterior coordinate was adjusted based on sex and body weight. After cannula implantation, a stylet was inserted into the guide until the microdialysis experiment. Each rat was individually housed in a cylindrical plastic cage for more than 6 days, as described previously.
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The day before microdialysis, the stylet was replaced with a dialysis probe that had a 1.0-mm-long semipermeable membrane (outer diameter 0.31 mm; AI-4-1, Eicom Co.). A 2-channel fluid swivel device (SSU-20, Eicom Co.) was connected to the inlet and outlet of the probe, and artificial CSF (147 mM NaCl, 4 mM KCl, 1.2 mM CaCl 2 , 0.9 mM MgCl 2 ) was infused through the probe at a rate of 1.2 μl/minute using a microdialysis pump (CMA/102, Carnegie Medicine AB). Each rat was maintained individually in its cage and dialysis was performed under unanesthetized, unrestrained conditions. 23 Following an overnight equilibrium period, six 36-µl samples were collected every 30 minutes over a 3-hour period and placed in vials containing an equal volume (36 μl) of acetic acid solution (40 mM) with EDTA (200 μM). Samples were stored at −70°C until the assay.
Dopamine concentration in the dialysate was quantified by high-performance liquid chromatography with a pump system (EP-300, Eicom Co.). Each 72-μl sample (36 μl dialysate plus 36 μl acetic acid solution) was injected into a precolumn (AC-ODS, Eicom Co.) with a mobile phase consisting of 0.1 M phosphate buffer at pH 6.0, 0.13 mM EDTA, 2.3 mM sodium-1-octanesulfonate, and 20% methanol. The dopamine was then separated out with a separation column (CA5-ODS, Eicom Co.) maintained at 25°C and detected with an electrochemical detector (ECD-300, Eicom Co.). The electrode potential was set to 400 mV against an Ag/AgCl reference electrode. The changes in electric current were recorded using an integrated data processor (Chromatocorder 12, System Instruments Co.). The dopamine concentration in the dialysate was calculated by reference to the peak area of the standard solution. The minimum detectability of dopamine was 0.14 pg/sample.
Immunohistochemical Analysis
One week after microdialysis, lesioned rats were perfused through the heart with 100 ml of saline followed by 300 ml of 4% paraformaldehyde. Brains were removed and immersed in 30% sucrose overnight at 4°C. Serial 20-µm coronal sections of a brain including the engrafted portion were made using a freezing microtome. After nonspecific antigenic proteins were blocked with 2% bovine serum albumin in 10% normal donkey serum, endogenous peroxidase was inactivated with 0.3% H 2 O 2 for 30 minutes at room temperature. Sections were incubated with 1:250 rabbit anti-TH as primary antibody overnight at 4°C. In negative control studies, phosphate-buffered saline was substituted for the antibodies. Sections were then incubated with secondary antibody for 3 hours at room temperature, and this was followed by incubation with peroxidase antiperoxidase complex. Specific immunoreactivity was visualized using diaminobenzidine.
Expression of TH and DAT in Hoechst-labeled transplanted SKPs was evaluated with double-labeling immunofluorescence staining against TH and DAT. Rabbit anti-TH and 1:250 rat monoclonal anti-DAT were used as the primary antibodies. We used 1:200 FITC-conjugated antirat IgG and 1:200 TRITC-conjugated anti-rabbit IgG as the secondary antibodies. Fluorescence signals of a single optical section were observed using a laser scanning confocal microscope with a sequential scanning model.
Statistical Analysis
All results are expressed as mean ± SEM. Numbers of rotation were compared using repeated-measures ANOVA. Extracellular dopamine levels were compared using a 2-tailed unpaired Student t-test. Correlations were examined using the Spearman rank correlation test. Values of p < 0.05 were considered significant.
Results
The VHL Peptide Binds to Elongin C and Induces Neuronal Differentiation of SKPs
To determine the localization of VHL peptide and phenotypic change in SKPs, immunocytochemistry was performed after incubation of SKPs with VHL peptide (Fig. 1A and B) . The FITC-linked VHL peptide was mainly detected in the cytoplasm, which frequently showed extending processes. These cells mostly expressed the neuronal marker MAP-2, whereas only a few cells expressed the glial marker, glial fibrillary acidic protein. Moreover, some of these cells also expressed the dopaminergic neuronal markers TH and DAT. These findings suggested that VHL peptide can induce SKPs to differentiate into neuronal cells, some of which also showed characteristics of dopaminergic neuronal cells. On the other hand, the expression of MAP-2, TH, and DAT was not detected in most SKPs not treated with VHL peptide. Western blot analysis showed that VHL peptide was abundant in cell lysates, corroborating the immunohistochemistry findings, and that some intracellular VHL peptide interacts with Elongin C (Fig. 1C) . These findings indicated that VHL peptide was efficiently delivered through the cellular membrane by TAT, bound to Elongin C, and then activated signal transduction for the initiation of neuronal differentiation.
Correlation of Functional Recovery in PD-Model Rats With Dopamine Levels in the Lesioned Striatum
Apomorphine-induced rotational behavior of 6-OHDA-lesioned rats in the VHL-SKP group was compared with that in SKP group rats ( Fig. 2A) . In the VHL-SKP group, the mean number of rotations per minute decreased from 8.5 ± 0.5 at transplantation to 6.6 ± 0.9 at 4 weeks after transplantation. In the SKP group, the mean number of rotations per minute increased from 9.5 ± 0.5 at transplantation to 10.2 ± 1.0 at 4 weeks after transplantation. These data led to a significant intergroup behavioral change (p = 0.03).
Extracellular dopamine levels in the lesioned striatum posttransplantation were evaluated by measuring dopamine volume in dialysate (Fig. 2B) . Dopamine levels in the VHL-SKP group and SKP group were 49.4 ± 13.2 and 6.84 ± 1.28 pg/ml, respectively. The difference in dopamine levels between the groups was also statistically significant (p = 0.001), suggesting that transplantation of VHL peptide-treated SKPs increased dopamine concentration in the lesioned striatum. Functional recovery after transplantation was determined on the basis of improved rotational behavior. The reduction in the numbers of apomorphine-induced rotations in each rat was plotted against the dopamine level in the engrafted striatum, and linear-regression analysis was performed (Fig. 2C) . These 2 parameters were significantly correlated (p = 0.02, r 2 = 0.36). Therefore, these data suggest that the increased dopamine production induced by transplantation of SKPs treated with VHL peptide contributes to behavioral recovery in the PD rats.
Differentiation of Transplanted SKPs Into Dopaminergic Neuronal Cells in the Lesioned Striatum
Six to 7 weeks after transplantation, histopathological analysis was performed to confirm the engrafted area and region sampled during microdialysis and to determine the survival and differentiation of transplanted SKPs in the lesioned striata of PD model rats. Following the microdialysis study, serial brain sections were investigated with immunohistochemistry. Engrafted portions were correctly located within the lesioned striatum in all the examined rats. These portions were identical to those analyzed with microdialysis. Survival of transplanted SKPs to various degrees was also observed along the needle tract in all rats in both VHL-SKP and SKP groups (Fig. 3A) . Although immunoreactivity for TH in the lesioned striatum was generally diminished, it was detected along the needle tract in VHL-SKP group rats; however, no immunoreactivity for TH was detected along the tract in rats of the SKP group (Fig. 3B) . Characteristics of dopaminergic neuronal cells were confirmed by double-labeling immunofluorescence staining for TH and DAT, specific markers of dopaminergic neuronal cells. Expression of both TH and DAT was limited within the area where transplanted SKPs migrated, and cells expressing TH were distributed similarly to those expressing DAT. Expression of TH and DAT was shown in the transplanted SKPs; moreover, the coexistence of these proteins was also commonly observed (Fig. 3C) . These findings suggest that SKPs treated with VHL peptide can survive and differentiate into phenotypes functioning as dopaminergic neuronal cells after transplantation to the lesioned striata of PD-model rats.
Discussion
In this study we showed, for the first time, that SKPs differentiate into dopaminergic neuronal cells that produce dopamine in the brains of PD-model rats, resulting in behavioral recovery. We emphasize that SKPs can be useful sources of new neurons for neurodegenerative disease owing to their accessibility. The authors of recent studies have reported that SKPs, which arise during embryogenesis and persist in the dermis and hair follicle into adulthood, can be easily isolated and cultured even from human skin tissue.
11,37 Skin-derived precursors were initially identified as a type of dermal cells that can grow in suspension as spheres in the presence of epidermal growth factor and fibroblast growth factor. These cells are self-renewing, multipotent precursors that express both nestin and fibronectin, the cell markers of neuronal stem cells and bone marrow mesenchymal stem cells, respectively; additionally they represent characteristics of embryonic neural crest-related precursors. Skin-derived precursors have been found to be able to differentiate into both neuronal and mesodermal progeny, including cell types that are normally not seen in the skin, such as neurons. 5, 36 There is no doubt that SKPs are much more accessible than other stem cells derived from neuronal tissue, bone marrow, and embryos. Obtaining stem cells other than SKPs requires invasive and difficult procedures; moreover, ethical and legal problems are likely to be involved, especially in obtaining and investigating embryonic tissues.
Parkinson disease symptoms are caused by a deficiency of dopamine in the striatum, and the dopamine concentration in the striata of patients with PD is usually less than 20% of that in healthy people. 29 Based on these findings, many dopamine sources for transplantation, which continuously produce dopamine and maintain the minimum dopamine concentration in striatum, have been investigated. 4 When undifferentiated stem cells are transplanted, they are supposed to have superior abilities to self-renew and differentiate appropriately to meet the demands of a host. Transplanted neuronal stem cells differentiate into dopamine neurons in the host striatum, resulting in functional recovery. 32 However, cultured stem cells cannot survive for a long period and tend to differentiate into glial cells after transplantation, suggesting that the potential for neuronal differentiation may be disturbed once they are cultured as spheres using growth factors.
31,34 Therefore, to effectively generate dopamine neurons surviving sufficiently in a host striatum, stem cells should be induced to differentiate into neurons before transplantation.
Many methods of generating dopamine neurons from stem cells have been reported. 2, 3, 14, 16, 28 It was notable in our previous study that VHL peptide can be easily synthesized and has the ability to induce neuronal differentiation without direct genetic control. 12 We used Tat protein, a popular cell-penetrating peptide, to deliver the small VHL peptide into stem cells without degradation. 17, 20 Our present study showed that VHL peptide effectively exists intracellularly after incubation with SKPs. Our method is very simple because it does not require specific viral vectors. Although there is much evidence that VHL protein plays an important role in neuronal differentia- tion, the molecular mechanism underlying this has not been clarified. 13, 24, 35 However, our studies have suggested that amino acids 157-171, amino acids of VHL protein (VHL peptide), mainly contribute to neuronal differentiation. 17 The VHL peptide is known to specifically bind to Elongin C. Activation of Elongin C by VHL peptide is necessary and sufficient for formation of the Elongin BC complex and subsequent ubiquitin-dependent signal regulation for cellular growth and differentiation. 15, 25 Our present study showed that VHL peptide binds to Elongin C in SKPs, suggesting that neuronal differentiation can be induced by activating signal pathways related to the Elongin BC complex. The Elongin BC complex binds to various kinds of multiproteins that can induce the ubiquitination and degradation of signal transducer and activator of transcription 3 (Stat 3). Signal transducer and activator of transcription 3 has been reported to promote glial differentiation in neuronal stem cells, and degradation of Stat 3 directly inhibits glial differentiation and accelerates neuronal differentiation. 8, 26 Further study will be required to investigate whether those pathways involving Stat 3 play an important role in neuronal differentiation induced by VHL peptide.
The microdialysis analysis in our present study showed that the behavioral improvement in our PD model in rats was correlated to dopamine concentrations in the lesioned striatum. Some previous studies have also shown similar results. 10, 30 It is understandable that increased dopamine can contribute to functional resolution of PD-like symptoms. However, motor complications such as dyskinesia can occur if grafted cells overgrow and release excessive dopamine, resulting in regional dopaminergic imbalance in the striatum. 6, 9 Therefore, ideal transplanted cells should work like intact dopamine neurons, which can produce and reuptake dopamine appropriately to generate physiological conditions. The increased dopamine can be produced by transplanted SKPs or residual original dopamine neurons in the striatum. Several neurotrophic factors, which are derived from various kinds of cell lines, have been found to protect against loss of dopamine neurons and restore the function of nigrostriatal dopamine pathways. 27 It is possible that transplanted SKPs secrete some neurotrophic factors and stimulate the surrounding damaged cells to produce dopamine. Although the source of dopamine cannot be clearly identified, our present study supports the idea that some of the increased dopamine is produced by transplanted SKPs because Hoechst-labeled transplanted SKPs express both TH and DAT, crucial factors for dopamine metabolism. This simultaneous expression of TH and DAT suggests that transplanted SKPs may differentiate into dopaminergic neuronal cells and have an ability to regulate extracellular dopamine in the host striatum. Although the reason SKPs transform into phenotypes of dopaminergic neuronal cells is not clear, VHL peptide might also contribute to the efficient generation of dopaminergic neuronal cells. Exogenous stem cells in vivo are likely to generate diverse cell types in response to environmental cues. 7, 36 Some studies have shown that stem cell-derived dopaminergic neuronal cells can be generated spontaneously after transplantation in a lesioned striatum, even without induction of differentiation in vitro. 1, 19, 32 These findings supported the notion that a lesioned striatum may provide a supportive environment that induces precursor cells to differentiate into dopaminergic neuronal cells because striatum is a target area of dopamine neurons. Although many intrinsic and environmental factors have been identified to induce the differentiation into dopaminergic neuronal cells, the mechanism of generating dopaminergic neuronal cells in vivo remains unclear.
28 Nevertheless, there is no doubt that neuronal differentiation prior to transplantation is important because stem cells tend to differentiate into glial cells in host brains. 34 Although many methods of generating dopamine neurons from stem cells have been reported, our method of inserting VHL peptides into SKPs using Tat protein could be a useful tool for inducing neuronal differentiation and generating dopaminergic neuronal cells.
There are some remaining issues pertaining to the strategy for stem cell transplantation in PD. 21 Transplanted cells can form tumors and migrate inappropriately outside the targeted striatum if they are incompletely differentiated before transplantation. Moreover, excessive or biased distribution of dopamine neurons can cause unexpected neurological complications. Before starting clinical trials, further experimental studies are required to establish an efficient method of generating dopaminergic neuronal cells and to improve the strategy of transplantation to obtain the maximum benefit with the minimum number of transplanted cells.
Conclusions
Our present study showed SKPs can differentiate into dopaminergic neuronal cells in the brains of PD-model rats, contributing to the improvement of PD-like symptoms. From clinical standpoint, we propose that SKPs can be useful sources of dopaminergic neuronal cells because they are easily accessible and free of ethical and legal problems associated with embryonic cell sources.
